Bariatric surgery improvements in type 2 diabetes persist at 5 years
Access to the full content of this site is available only to registered healthcare professionals.
Register to read more
Bariatric surgery is a durable option for treating type 2 diabetes (T2D).
Why this matters
T2D incurs high morbidity and costs.
Outcomes assessed at 5 y for 134 patients with T2D with baseline BMI 27-43 kg/m2, randomly assigned to intensive medical therapy alone or combined with either Roux-en-Y gastric bypass or sleeve gastrectomy.
Funding: Ethicon Endo-Surgery, LifeScan, Cleveland Clinic, and NIH.
Primary outcome, HbA1c ≤6.0% at 5 y without medication use, achieved in 5% of 38 in medical therapy group vs 29% of 49 with gastric bypass and 23% of 47 with sleeve gastrectomy (P=.03).
Diabetes duration <8 y and random assignment to gastric bypass alone were the only significant predictors of achieving HbA1c ≤6.0% (P=.007 and P=.03, respectively).
After 5 y, patients in the surgery groups were significantly more likely to achieve HbA1c ≤6.0% without diabetes med...